+39 02 610346.1 - info@newron.com Glossary | Sitemap | Cookie policy Home About Us Research and Drug Development Investors and Media Contact Us ‹ › Discovering and developing innovative therapeutics for CNS disorders Welcome to the Newron Pharmaceuticals website. We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain. LATEST PRESS RELEASES 6 OCT Newron Pharmaceuticals Supports Rett Syndrome Awareness Month this October 26 SEP Newron raises CHF 27.0 Million in a private placement of new shares. 26 SEP Newron raises CHF 27.0 Million in a private placement of new shares 25 SEP Newron launches a private placement of new shares. 25 SEP Newron launches a private placement of new shares 14 SEP Newron reports half-year 2017 results View All NEWRON SHARE PRICE EVENTS 27 NOV German Equity Forum 2017 Nov, 27-29, 2017 - Frankfurt 15 NOV Jefferies 2017 London Healthcare Conference Nov, 15-16, 2017 - Waldorf Hilton, London 20 SEP Investora 2017 Sept. 20-21, 2017 - Zurich, CH View Event Calendar About Us Overview Strategy Our people History Research & Drug Development Therapeutic Focus Pipeline Partners Publications Media News Events Reports, presentations & webcasts Email alert Investors Stock information Financial Calendar Financial Report Shareholder FAQs Disclaimer ©2017 - Newron Pharmaceuticals SPA. All Rights Reserved - VAT: IT 02479490126

+39 02 610346.1 - info@newron.com Glossary | Sitemap | Cookie policy Home About Us Research and Drug Development Investors and Media Contact Us Pipeline Research and Drug Development / Pipeline Overview Therapeutic Focus Pipeline Pipeline chart Safinamide Sarizotan NW-3509 Ralfinamide Partners Publications Clinical Trials Patient Resources Pipeline Newron has built a well-balanced pipeline of innovative CNS and pain treatments, including safinamide for Parkinson’s disease, licensed to Zambon Group and Meiji Seika Pharma, for which CHMP has recommended approval in the EU and filing submitted to FDA and Swissmedic; sarizotan for Rett syndrome, ralfinamide for specific pain indications, and NW-3509 as, potentially, the first add-on therapy for the treatment of schizophrenia. About Us Overview Strategy Our people History Research & Drug Development Therapeutic Focus Pipeline Partners Publications Media News Events Reports, presentations & webcasts Email alert Investors Stock information Financial Calendar Financial Report Shareholder FAQs Disclaimer ©2017 - Newron Pharmaceuticals SPA. All Rights Reserved - VAT: IT 02479490126